Navigation Links
Orexigen(R) Therapeutics Announces Changes to Its Clinical Programs and Management Team
Date:12/5/2008

parting group, for their extensive contributions to Orexigen. We believe we are in a very favorable position largely as a result of their efforts."

The Company is directing all of its efforts and resources to Contrave(R) and Empatic(TM), its obesity product candidates. It anticipates announcing the results from the first Phase 3 clinical trial for Contrave in January.

About Orexigen Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead combination product candidates are Contrave, which is in Phase 3 clinical trials, and Empatic, which is in the later stages of Phase 2 clinical development. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss. Further information about the company can be found at http://www.orexigen.com.

Forward-Looking Statements

Orexigen cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "indicates," "will," "intends," "potential," "suggests," "assuming," "designed" and similar expressions are intended to identify forward-looking statements. These statements are based on the Company's current beliefs and expectations. These forward-looking statements include statements regarding the objectives of the Company's organizational changes, the enrollment, timing, execution, completion and announcement of results of clinical trials of Contrave and the potential to obtain regulatory approval for, and effectively treat obesity with its product candidates. The inclusion of forward-looking statements should not be regarded as a representation by Orexigen that any of its plans
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Orexigen(R) Initiates Second Phase IIb Empatic(TM) Trial on Schedule
2. Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R)
3. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
6. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
7. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
8. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
9. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
10. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
11. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... and NEW YORK and ... As the leading distributor of market intelligence, MarketResearch.com is ... report by IQ4I Research and Consultancy focusing on the ... more about IQ4I Research visit: http://www.marketresearch.com/land/publisher.asp?vendorid=4023&progid=86891 . ... Pharmaceutical Ingredients Global Market – Forecast to 2020 ...
(Date:11/26/2014)...  goBalto, Inc., the leading provider of cloud-based clinical ... of Red Herring,s Top 100 Global award. ... award in 2013, marking its emergence as a top ... Herring,s Top 100 Global list has become a mark ... Red Herring editors were among the first to recognize ...
(Date:11/26/2014)... 25, 2014 Nanomix Inc., (Nanomix), ... development of mobile diagnostic tests to enable ... and pre-hospital settings, today announced it has ... The certification was awarded by the British ... leading certification bodies. ISO ...
Breaking Medicine Technology:MarketResearch.com: Active Pharmaceutical Ingredient Market to Reach $175 Billion by 2020 Says IQ4I Report 2MarketResearch.com: Active Pharmaceutical Ingredient Market to Reach $175 Billion by 2020 Says IQ4I Report 3goBalto Selected as a 2014 Red Herring Top 100 Global Company 2goBalto Selected as a 2014 Red Herring Top 100 Global Company 3Nanomix Receives ISO 13485:2003 Certification 2
(Date:11/28/2014)... Dr. Andrew Campbell, one of the ... of Quintessa Aesthetic Center into a third location in ... N1497 Golf Road in Suite 200 and will open ... new Delafield location will offer a variety of ... filler injectables , micro laser peels, chemical peels, ...
(Date:11/28/2014)... November 28, 2014 Secura Consultants, ... few insurance marketing organizations in the country focused ... asset protection marketplace. Secura Consultants is proud to ... Principal Financial Group, a leading global financial company. ... interests. With the ownership interest comes the need ...
(Date:11/28/2014)... November 28, 2014 Not only is ... products free of petroleum, parabens and other cancer-causing agents, ... fund research, education and awareness programs that help in ... and owners have raised an incredible, record-breaking contribution of ... Cure, sales of the Sweet Red Rose Whip Moisturizer ...
(Date:11/28/2014)... York (PRWEB) November 28, 2014 ... ) have now been filed in a New ... metal implants, Bernstein Liebhard LLP reports. , ... Bergen County Superior Court reflects the filing of ... modular-neck hip stems, which were voluntarily recalled on ...
(Date:11/28/2014)... "Most of my life, I have suffered ... said an inventor from Findlay, Ohio. "I thought that there ... my foot, which inspired me to invent this accessory." , ... way to support an injured foot. The sling makes it ... need for crutches. The design redistributes weight so that the ...
Breaking Medicine News(10 mins):Health News:Dr. Andrew Campbell to Expand Quintessa Aesthetic Center into Delafield 2Health News:Secura Consultants Offers Complimentary Buy-Sell Agreement Reviews 2Health News:Éminence Organic Skin Care Donates Record-breaking $30,000 to Breast Cancer Research 2Health News:Éminence Organic Skin Care Donates Record-breaking $30,000 to Breast Cancer Research 3Health News:More than 2,100 Stryker Hip Lawsuits Included in New Jersey Litigation after Settlement Announcement, Bernstein Liebhard LLP Reports 2Health News:More than 2,100 Stryker Hip Lawsuits Included in New Jersey Litigation after Settlement Announcement, Bernstein Liebhard LLP Reports 3
... works, the greater his chances for high blood pressure, a new ... at the// University of California, Irvine analyzed more than 24,000 people ... found that people who worked 40 hours a week are 14 ... who work under 39 hours a week. Those who work 41 ...
... from Rensselaer Polytechnic Institute in Troy, N.Y., and the University ... the host receptors where anthrax toxin attaches in the body. ... bind to multiple sites on the host receptor making it ... site. The researchers found that the new approach led ...
... doctors were stranded for days at the Charity Hospital, when ... of the storm, Charles Gibson reports from that hospital. ... might think you're in a warehouse or some kind of ... ,Charity Hospital served the poor and uninsured people ...
... conjoined twins were separated after a lengthy surgery. 3 weeks ... to their father, it is an indication of their recovery., ... were conjoined at the trunk and shared several internal organs, ... various medical complications caused by the only kidney, the surgery ...
... draw a little closer in understanding the evolution of the ... be more infectious to people. ,According to ... influenza strains from the common human influenza. This conclusion follows ... type flu viruses. This analysis will also aid scientists trace ...
... the Northern Territory Government’s decision to fund rotavirus ... to follow suit and help// protect vulnerable children ... came after the Federal Government’s Pharmaceutical Benefits Advisory ... cost-effective to provide the rotavirus vaccine to all ...
Cached Medicine News:Health News:Inhibitor That Blocks Host Receptors Found To be Effective In Treating Anthrax 2Health News:Conjoined twins doing well after separation 2Health News:Understanding the Evolution of Viruses a little more Clearly 2
Lumbar Allograft with Osteoactive advantage. Promotes bone formation and faster incorporation. Derived from the proven technology behind Grafton DBM. Maintains structural integrity and strength....
... offers strength and radiolucent capabilities for ... titanium microdiscectomy system for microscope-aided repair ... less invasive procedures with reduced patient ... provide low profile, unobstructed retraction capabilities ...
Valin Hemilaminectomy Retractor, self retaining with rack and pinion action....
Karlin Crank Frame Spinal Retractor Set is designed for posterior lumbar and thoracic spine surgery. Arm design allows the blades be pre-positioned in the wound prior to attachment....
Medicine Products: